Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?

Yazar
Demır, Gokhan
Okkan, Sait
Tecımer, Coskun
Ozmen, Vahit
Eralp, Yesim
Pılancı, Kezban Nur
Alco, Gul
Ordu, Cetin
Sarsenov, Dauren
Celebı, Filiz
Erdogan, Zeynep
Agacayak, Filiz
Ilgun, Serkan
Üst veri
Tüm öğe kaydını göster
Özet
One of the most important adverse effects of zoledronic acid (ZA) is osteonecrosis of the jaw (ONJ). In previous literature, several risk factors have been identified in the development of ONJ. In this study, we aimed to determine the role of trastuzumab, an antiangiogenic agent, as an independent risk factor for the development of this serious side effect.
Bağlantı
http://hdl.handle.net/20.500.12627/67735
https://doi.org/10.1097/md.0000000000000671
Koleksiyonlar